SOST and metabolic dysfunction-associated steatotic liver disease: Our study may suggest that in normal subjects without NAFLD, these metabolic indexes showed no obvious influence on sclerostin secretion, while in NAFLD subjects, these multiple metabolic abnormalities may inhibit sclerostin secretion mediated by a direct or indirect mechanism.